About FDA

Division of Metabolism and Endocrinology Products (DMEP)

Director: Jean-Marc Guettier, M.D. 

Deputy Director: Eric Colman, M.D. 
Deputy Director for Safety: Amy Egan, M.D. 
Chiefs, Project Management Staff: Julie Van der Waag, M.P.H., Pamela Lucarelli
Safety Regulatory Project Manager: Mehreen Hai, Ph.D.  
The Division of Metabolism and Endocrinology Products (DMEP) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics Licensing Applications (BLAs) for drugs and biologics intended for the prevention, treatment, or diagnosis of conditions including:
  • Type 1 and Type 2 diabetes mellitus, including insulins and glucagons
  • Weight loss and weight maintenance
  • Acromegaly
  • Growth hormone deficiency (GHD) and growth hormone-related conditions, including pediatric GHD-related short stature, adult GHD, Prader-Willi syndrome, small for gestational age without catch-up growth by age 2 years, Turner syndrome, pediatric renal insufficiency, idiopathic short stature, AIDS wasting and cachexia, achondroplasia 
  • Hypercholesterolemia
  • Adrenal and ACTH disorders
  • Anabolic steroids
  • Cachexia
  • Hypo- and hyperthryoidism
  • Hyperparathyroidism
  • Developmental disorders (accelerated or delayed puberty)
  • Cushings sundrome
  • Geriatric frailty and sarcopenia
  • Lipodystrophy
  • Vasopressins (central diabetes insipidus, noctural enuresis)
  • Vitamin deficiency (except vitamin D) 
Mailing Address:
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Metabolism and Endocrinology Products
5901-B Ammendale Road
Beltsville, MD 20705-1266
Phone: (301) 796-2290
Fax: (301) 796-9712

Page Last Updated: 12/16/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.